Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study

Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study – FreYAG1 study

Published:2023-10-16 Issue:1 Volume:23 Page:
ISSN:1471-2415
Container-title:BMC Ophthalmology
language:en
Short-container-title:BMC Ophthalmol

Author:

Brézin Antoine P.,Labbe Antoine,Schweitzer Cédric,Lignereux François,Rozot Pascal,Goguillot Mélanie,Bugnard Françoise,Dot Corinne

Abstract

Abstract Rationale Nd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is the gold standard for the treatment of PCO (Posterior Capsule Opacification). There is a lack of real-world data about Nd:YAG-caps use. Purpose This study’s objectives were to estimate Nd:YAG-caps incidence in France, to describe the patient characteristics, and to analyze the time between surgeries and capsulotomies. Setting: The study was based on data extracted from the EGB database, a 1/97th sample representative of the French population. Design: observational, retrospective, cohort study using national claims data. Methods French adult patients who underwent Nd:YAG-caps between 2014 and 2017 were selected. Main outcomes were the number of patients and procedures performed and the risk factors associated with early Nd:YAG-caps. Results: During the study period, Nd:YAG-caps were performed in 8,425 patients accounting for 10,774 procedures. The extrapolation to the French population led to estimate that 253.103 patients had Nd:YAG-caps, representing 312.103 procedures in 2017. The mean age at Nd:YAG-caps was 75.1 (± 10.2) years. About 36% of patients presented at least one ocular comorbidity. Nd:YAG-caps was performed within 2 years after surgery in 33.0% of patients and within one year in 9.8% of patients. Patients with Nd:YAG-caps within the first year (OR CI95 0.721 [0.673–0.772]) or in the first two years (OR CI95 0.721 [0.673–0.772]) were younger than patients with later Nd:YAG-caps and had a more frequent history of treated ocular diseases (OR 1.516 and 1.178, respectively). Conclusions This study brought new real-world and large-scale data regarding Nd:YAG-caps use and gave an updated insight into the patients’ characteristics.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology,General Medicine

Link

https://link.springer.com/content/pdf/10.1186/s12886-023-03134-6.pdf

Reference39 articles.

1. Caisse Nationale d’Assurance Maladie. Actes techniques de la CCAM en 2021 | L’Assurance Maladie. https://assurance-maladie.ameli.fr/etudes-et-donnees/actes-techniques-ccam-2021. Accessed 5 Oct 2022.

2. Agence Technique de l’Information sur l’Hospitalisation. Open CCAM 2021 | Stats ATIH. https://www.scansante.fr/mco-actes-ccam-par-etablissements/open-ccam-2021. Accessed 5 Oct 2022.

3. Ayed T, Rannen R, Naili K, Sokkah M, Gabsi S. [Risk factors for secondary cataract: a case-control study with multivariate analysis]. J Fr Ophtalmol. 2002;25:615–20.

4. Benzerroug M, Milazzo S. La cataracte secondaire. EMC Ophtalmologie. 2014;11.

5. Royal College of Ophthalmologists. RCOphth NOD PCO Report 2021.pdf. https://www.nodaudit.org.uk/u/docs/20/rijbxkcubs/RCOphth%20NOD%20PCO%20Report%202021.pdf. Accessed 5 Dec 2022.